Selective Internal Radiation Therapy (SIRT) Using SIR-Spheres® Y-90 Resin Microspheres on DoR & ORR in Unresectable Hepatocellular Carcinoma Patients
Active, not recruiting · Not applicable · NCT04736121
Conditions: Unresectable Hepatocellular Carcinoma, BCLC Stage A Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma
At a glance
- Research payments reported, 2025
- $251,524
- U.S. investigators named
- 12
- Sites paid
- 13
- Planned or actual enrollment
- 100
About the trial
- Sponsor
- Sirtex Medical (with Bright Research Partners)
- Tested
- Resin microspheres containing yttrium-90 (Y-90) (device)
- Dates
- Started 2021-05-28; completion 2026-09
- Results posted
- Not yet
The objective of this pivotal study is to evaluate the safety and effectiveness of SIRT using SIR-Spheres Y-90 resin microspheres as first-line treatment for local control of HCC in patients with Barcelona Clinic Liver Cancer (BCLC) stage A, B1, B2, and C. SIR-Spheres consist of biocompatible resin microspheres containing yttrium-90 (Y-90), with a size between 20 and 60 microns in diameter. Y-90 is a high-energy pure beta-emitting isotope with no primary gamma emission. SIR-Spheres are indicated for the local tumor control of unresectable hepatocellular carcinoma (HCC) in patients with Barcelona Clinic Liver Cancer (BCLC) stage A, B1 and B2, maximal single lesion size of 8 cm, no macrovas…
From ClinicalTrials.gov, last updated 2026-02-03. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Sirtex Medical Inc reported $251,524 in research payments for this study in 2025 (67 payments).
Products named: Sir-Spheres Microspheres
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Nadine Abi-jaoudeh, MD Interventional Radiology · Orange, CA
- Ripal T. Gandhi, M.D. Interventional Radiology · Miami, FL
- Nima Kokabi, MD Interventional Radiology · Atlanta, GA
- Ammar Sarwar, M.D. Interventional Radiology · Boston, MA
- Eric P. Wehrenberg-klee, M.D. Radiology · Boston, MA
- Sameer D. Gadani, MD Interventional Radiology · Minneapolis, MN
- Andrew J. Klobuka, M.D. Interventional Radiology · Pittsburgh, PA
- Gregory J. Nadolski II, MD Interventional Radiology · Philadelphia, PA
- Aaron W. Maxwell, M.D. Interventional Radiology · Providence, RI
- Armeen Mahvash, MD Interventional Radiology · Houston, TX
- Parvez Mantry, MD Gastroenterology · Dallas, TX
- David M. Mauro, M.D. Radiology · Charlottesville, VA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Beth Israel Deaconess Medical Center, MA $74,732
- Uci Health-Orange, CA $28,977
- Unc Hospitals, NC $23,288
- Rhode Island Hospital, RI $21,552
- Ut MD Anderson Cancer Center $19,502
- Dana-Farber Cancer Institute $18,423
- Cleveland Clinic, OH $15,705
- Pennsylvania Hospital, PA $12,642
- Allegheny General Hospital, PA $9,734
- Emory University Hospital, GA $9,676
- Methodist Dallas Medical Center, TX $9,202
- Baptist Health Medical Center - Jacksonville, FL $7,906
- Harris County Psychiatric Center, TX $185
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.